Аторвастатин в лечении больных сахарным диабетом 2-го типа (к 30-летию открытия статинов)
- Авторы: Галявич А.С1
-
Учреждения:
- Казанский государственный медицинский университет
- Выпуск: Том 8, № 9 (2006)
- Страницы: 54-57
- Раздел: Статьи
- URL: https://bakhtiniada.ru/2075-1753/article/view/92226
- ID: 92226
Цитировать
Полный текст
Аннотация
Класс статинов весьма неоднороден по своей химической структуре и клиническим эффектам. Одним из наиболее часто применяемых статинов является аторвастатин. За годы его применения накоплено достаточное количество фактов, подтверждающих положительные и многообразные эффекты этого препарата, в том числе при сахарном диабете (СД) типа 2.Эффективность применения аторвастатина у больных СД типа 2 подтверждается достаточным количеством исследований.
Ключевые слова
Полный текст
Открыть статью на сайте журналаСписок литературы
- Endo A, Kuroda M, Tsujita Y. ML-236A, ML 236B, ML 236C, new inhibitors of cholesterogenesis produced by Penicillinum citrinum. J Antibiot 1976; 29: 13246–8.
- Rosenson R. Non - lipid - lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999; 1: 225–32.
- Галявич А.С. Место статинов в терапии больных сахарным диабетом 2-го типа. ConsiliumMedicum 2005; 9: 754–7.
- Grandy S.M, Howard B, Smith S.Jr et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105: 2231–9.
- Dyslipidemia Management in Adults With Diabetes. Diabetes Care 2004; 27: S68–71.
- Sever P.S, Poulter N.R, Dahlof B et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial - lipid - lowering arm (ASCOT-LLA). Diabetes Care 2005; 28 (5): 1151–7.
- Shepherd J, Barter P, Carmena R et al. For the Treating to New Targets Investigators. Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes. The Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220–6.
- Knopp R, d’Emden M, Smilde J, Pocock S. On behalf of the ASPEN Study Group. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care 2006; 29: 1478–85.
- Colhoun H.M, Betteridge D.J, Durrington P.N et al. The CARDS Investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo - controlled trial. Lancet 2004; 364: 685–96.
- Soedamah-Muthu S.S, Colhoun H.M, Thomason M.J et al. CARDS Investigators. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis. 2003; 167 (2): 243–55.
- Athyros V.G, Papageorgiou A.A, Mercouris B.R et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease revention: The GREek Atorvastatin and Coronary - heart - disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220–8.
- Wang T.J, Larson M.G, Levy D et al. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. Circulation 2002; 106: 1189–91.
- van de Ree M.A, Huisman M.V, Princen H.M et al. DALI-Study Group. Strong decrease of high sensitivity C-reactive protein with high - dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis. 2003; 166 (1): 129–35.
- Yamada S,Yanagawa T, Sasamoto K et al. Atorvastatin lowers plasma low - density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. Metabolism 2006; 55 (1): 67–71.
- Chu C.S, Lee K.T, Lee M.Y et al. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2006; 97 (5): 646–50.
- Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–5.
- Lam H.C, Chu C.H, Wei M.C et al. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia. Exp Biol Med (Maywood). 2006; 231 (6): 1010–5.
- Shinohara K, Shoji T, Kimoto E et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2005; 12 (4): 205–10.
- Saydah S.H, Fradkin J, Cowie C.C. Poor control of risk factors vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335–42.
- Oborne C.A, Philbin M. Application of evidence - based criteria of appropriate aspirin and appropriate lipid - lowering therapy in diabetic inpatients. Int J Pharmacy Practice 2003; 11: R73.
- Leiter L.A, Betteridge D.J. AUDIT Investigators. The AUDIT Study: a worldwide survey of physicians attitudes about diabetic dyslipidaemia. Diabetes 2004; 53 (suppl. 2): A285.
Дополнительные файлы
